While clinical trials have noted a benefit of the sGC stimulators riociguat and vericiguat on the treatment of pulmonary hypertension and heart failure with reduced ejection fraction, there is a relative paucity of clinical investigations focused on the effects of sGC stimulation and sGC activation on clinically significant IR injury. Here, SGCB is linked to pulmonary arterial hypertension.